These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31712213)

  • 1. Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses
    Amblard F; Boucle S; Bassit L; Cox B; Sari O; Tao S; Chen Z; Ozturk T; Verma K; Russell O; Rat V; de Rocquigny H; Fiquet O; Boussand M; Di Santo J; Strick-Marchand H; Schinazi RF
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.
    Lahlali T; Berke JM; Vergauwen K; Foca A; Vandyck K; Pauwels F; Zoulim F; Durantel D
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus.
    Berke JM; Dehertogh P; Vergauwen K; Van Damme E; Mostmans W; Vandyck K; Pauwels F
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
    Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
    Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator.
    Hurwitz SJ; McBrearty N; Arzumanyan A; Bichenkov E; Tao S; Bassit L; Chen Z; Kohler JJ; Amblard F; Feitelson MA; Schinazi RF
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33467678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.
    Mani N; Cole AG; Phelps JR; Ardzinski A; Cobarrubias KD; Cuconati A; Dorsey BD; Evangelista E; Fan K; Guo F; Guo H; Guo JT; Harasym TO; Kadhim S; Kultgen SG; Lee ACH; Li AHL; Long Q; Majeski SA; Mao R; McClintock KD; Reid SP; Rijnbrand R; Snead NM; Micolochick Steuer HM; Stever K; Tang S; Wang X; Zhao Q; Sofia MJ
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level
    Berke JM; Tan Y; Sauviller S; Wu D-t; Zhang K; Conceição-Neto N; Blázquez Moreno A; Kong D; Kukolj G; Li C; Zhu R; Nájera I; Pauwels F
    J Virol; 2024 Mar; 98(3):e0150223. PubMed ID: 38315015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection.
    Ko C; Bester R; Zhou X; Xu Z; Blossey C; Sacherl J; Vondran FWR; Gao L; Protzer U
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
    Shi M; Sun WL; Hua YY; Han B; Shi L
    PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.
    Berke JM; Dehertogh P; Vergauwen K; Mostmans W; Vandyck K; Raboisson P; Pauwels F
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.
    Burdette D; Hyrina A; Song Z; Beran RK; Cheung T; Gilmore S; Kobayashi T; Li L; Liu Y; Niedziela-Majka A; Medley J; Mehra U; Morganelli P; Novikov N; Niu C; Tam D; Tang J; Wang J; Yue Q; Fletcher SP; Holdorf MM; Delaney WE; Feierbach B; Lazerwith S
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0134822. PubMed ID: 36519892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Discovery of
    Yang Y; Yan Y; Yin J; Hu J; Cai X; Hu J; Xia J; Wang K; Tang N; Huang L
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
    Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
    Sheraz M; Cheng J; Tang L; Chang J; Guo JT
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line.
    Ogura N; Watashi K; Noguchi T; Wakita T
    Biochem Biophys Res Commun; 2014 Sep; 452(3):315-21. PubMed ID: 25150444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The premise of capsid assembly modulators towards eliminating HBV persistence.
    Bassit L; Amblard F; Patel D; Biteau N; Chen Z; Kasthuri M; Zhou S; Schinazi RF
    Expert Opin Drug Discov; 2023; 18(9):1031-1041. PubMed ID: 37477111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents.
    Amblard F; Boucle S; Bassit L; Chen Z; Sari O; Cox B; Verma K; Ozturk T; Ollinger-Russell O; Schinazi RF
    Bioorg Med Chem; 2021 Feb; 31():115952. PubMed ID: 33421915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.